Safety and Efficacy of Dabigatran for the Peri-Procedural Anticoagulation in Patients Undergoing Abla-Tion of Atrial Tachyarrhythmias

Zhou Gaojun,Yang Bing,Li Mingfang,Zhang Fengxiang,Ju Weizhu,Chen Hongwu,Yang Gang,Gu Kai,Xie Xin,Guo Yanru,Cao Kejiang,Chen Minglong
DOI: https://doi.org/10.3760/cma.j.issn.1007-6638.2016.01.016
2016-01-01
Abstract:Objective To evaluate the safety and efficacy of dabigatran for the peri-procedural antico-agulation in patients with atrial tachyarrhythmias ( ATA) undergoing radiofrequency catheter ablation ( RFCA) . Methods From September 2013 to April 2015,859 patients who underwent RFCA of ATA in the First Affilia-ted Hospital of Nanjing Medical University were retrospectively reviewed. Among them,165 patients administra-ted with dabigatran were defined as Dabigatran group,and another 165 patients taking warfarin matched with age (±3years),sex,type of ATA,and comorbidities were defined as Warfarin group. We evaluated detailed peri-procedural anticoagulation regimens, and compared the incidence of thromboembolic events, major and minor bleeding events and other adverse effects of drugs between these two groups. Results Compared to Warfarin group,Dabigatran group had significantly lower level of the baseline activated clotting time (ACT)[(143. 6± 24. 9)s vs(197. 8±59. 9)s,P<0. 001],target ACT for the first time[(281. 1±26. 7)s vs(311. 4±40. 8)s,P<0. 001],peak value of ACT[(290. 1±31. 3)s vs(325. 3±39. 1)s,P<0. 001] (P<0. 001). However,the hepa-rin dose throughout procedure was significantly higher in Dabigatran group[(8979. 0±3241. 2)U vs(5592. 0± 3251. 1)U,P<0. 001]. There was no thrombembolic event in both groups. Totally,28(17%,2 major)and 19 ( 11. 5%,2 major) hemorrhagic complications occurred in Warfarin and Dabigatran groups,respectively. The to-tal incidence of thromboembolic and hemorrhagic complications were similar in both groups( P>0. 05) . The in-cidence of gastrointestinal adverse events was significantly higher in Dabigatran group compared with Warfarin group (9. 1% vs. 0,P<0. 001). Conclusion This study demonstrated that dabigatran had similar safety and efficacy compared with warfarin for the peri-procedural anticoagulation in patients undergoing RFCA of ATA, and carefully monitoring the ACT during the procedure should be emphasized to titrate appropriate heparin dose.
What problem does this paper attempt to address?